<DOC>
	<DOCNO>NCT01838200</DOCNO>
	<brief_summary>This open-label , dose-escalation , non-randomized , phase I study patient histologically confirm Stage III IV melanoma least three metastatic cutaneous subcutaneous lesion suitable : intralesional ( IL ) injection ( 1 lesion ) , accessible biopsy ( 1 lesion ) , response evaluation RECIST ( v1.1 ) modify RECIST ( irRC ) ( 1 lesion ) . The primary objective determine whether IL administration BCG follow intravenous ( IV ) infusion ipilimumab safe . Ipilimumab ( YERVOY® ) monoclonal anti-CTLA-4 antibody approve FDA TGA anticancer therapy melanoma . Secondary objective study : ) clinical efficacy , document whether combination therapy induce tumour response ; b ) immunogenicity , identify combination induces immune response tumour . All patient include analysis efficacy immunogenicity . Cohort 1 ( 9 patient &lt; 10mm induration tuberculin Purified Protein Derivative [ PPD ] test ) : Group 1 ( 3 patient ) receive one IL injection 200 µl BCG contain 0.16 - 0.64 x 106 cfu follow four IV infusion 3 mg/kg ipilimumab every 3 week , start day 36 . Group 2 ( 3 patient ) 3 ( n=3 ) receive 200 µl BCG contain 0.8 - 3.2 x 106 cfu 4.0 -16.0 x 106 cfu , respectively , follow ipilimumab regimen . Safety evaluate cohort . Cohort 2 ( 9 patient ≥10mm induration PPD test ) : Enrolment start final patient Cohort 1 , Group 1 reach study week 7 . Then enrolment proceed parallel Cohort 2 Cohort 1 Groups 2 3 . Patients receive 0.16 -0.64 x 106 cfu BCG follow four IV infusion 3 mg/kg ipilimumab every 3 week , start day 36 . Evaluation safety cohort observational .</brief_summary>
	<brief_title>A Phase I Study Intralesional Bacillus Calmette-Guerin ( BCG ) Followed Ipilimumab Therapy Patients With Advanced Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>BCG Vaccine</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically confirm stage III ( unresectable ) stage IV melanoma Minimum one metastatic lesion , cutaneous subcutaneous , ideally three lesion , accommodate IL injection ( 1 lesion ) , accessibility biopsy ( 1 lesion ) , evaluability response RECIST v.1.1 ( 1 lesion ) modify RECIST ( irRC ) . Performance status ECOG 01 Within last 2 week prior study day 1 , vital laboratory parameter within normal range , except follow laboratory parameter , within range specify : Haemoglobin : ≥ 100 g/L , Platelets : ≥ 100 x 10^9/L , INR : ≤ 2.0 , Creatinine : ≤ 120 µmol/L , Bilirubin : ≤ 30 µmol/L , eGFR : &gt; 0.75 x LLN , ALT/AST : ≤ 2.0 x ULN , Albumin : &gt; 28 g/L , Neutrophils : &gt; 1.5 x 10^9/L , Lymphocytes : &gt; 0.9 x 10^9/L , Active cerebral metastasis unless stable radiation least one month require corticosteroid treatment 30 day prior enrolment Other know malignancy within 3 year prior entry study , except treat nonmelanoma skin cancer cervical carcinoma situ . History tuberculosis History hypersensitivity BCG Any contraindication use isoniazid Generalized skin disease Autoimmune disease : Patients history inflammatory bowel disease , include ulcerative colitis Crohn 's Disease , exclude study , patient history symptomatic disease ( eg , rheumatoid arthritis , systemic progressive sclerosis [ scleroderma ] , systemic lupus erythematosus , autoimmune vasculitis [ eg , Wegener 's Granulomatosis ] ) ; motor neuropathy consider autoimmune origin ( e.g . GuillainBarre Syndrome Myasthenia Gravis ) . Exceptions : vitiligo , type I diabetes , pernicious anaemia ( treat ) . Any underlying medical psychiatric condition , opinion investigator make administration ipilimumab hazardous obscure interpretation AEs , condition associate frequent diarrhea . Prior immunotherapy systemic adjuvant therapy melanoma follow recent relapse and/or resection melanoma Prior treatment CTLA4 inhibitor Concomitant therapy following : IL2 , interferon , nonstudy immunotherapy regimen ; cytotoxic chemotherapy ; immunosuppressive agent ; investigation therapy ; chronic use systemic corticosteroid Known HIV positivity , Hepatitis B Hepatitis C Chemotherapy radiation therapy within precede 4 week ( 6 week nitrosourea drug ) . Lack availability immunological clinical followup assessment . Participation clinical trial involve another investigational agent within 4 week prior first dose . Mental impairment may compromise ability give informed consent comply requirement study . Women pregnant ( positive pregnancy test baseline ) , breastfeed Men woman unwilling unable use acceptable method contraception avoid pregnancy entire study period least 8 week cessation study drug . Prisoners subject compulsorily detain ( involuntarily incarcerate ) treatment either psychiatric physical ( e.g. , infectious ) illness .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>BCG</keyword>
	<keyword>Bacillus Calmette-Guérin</keyword>
	<keyword>Ipilimumab</keyword>
	<keyword>YERVOY</keyword>
	<keyword>Advanced Metastatic Melanoma</keyword>
	<keyword>Metastatic Melanoma</keyword>
</DOC>